Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00107523 · ClinicalTrials.gov registry record · Phase 1
Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00107523: Completed Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
NCT00107523 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00107523, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Pravastatin may help idarubicin and cytarabine work better by making cancer cells more sensitive to the drugs. Giving pravastatin together with idarubicin and cytarabine may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of pravastatin when given together with idarubicin and cytarabine in treating patients with acute myeloid leukemia.
Interventions
- DRUG cytarabine
- DRUG idarubicin
- DRUG pravastatin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-01 |
| Est. Completion | 2005-10 |
| Phase | Phase 1 |
What the finished NCT00107523 record still lists
NCT00107523 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which cytarabine is the first listed.
NCT00107523 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00107523 about?
NCT00107523 is a clinical study titled "Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia". RATIONALE: Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Pravastatin may help idarubicin and cytarabine work better by making cancer cells more sensitive to the ...
What is the current status of trial NCT00107523?
This trial is currently completed. It is a Phase 1 study. The study started on 2005-01. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00107523?
The interventions under investigation include: cytarabine (DRUG), idarubicin (DRUG), pravastatin (DRUG).
Who is sponsoring clinical trial NCT00107523?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia